You are here

FDA Agrees to Review Insulin Inhalation Powder, Afrezza

Approval decision slated for April 2014 (October 30)

The FDA has acknowledged the resubmission of a New Drug Application (NDA) for Afrezza (insulin human [rDNA origin]) inhalation powder (Mannkind Corporation).

The agency considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011. The user fee goal date is April 15, 2014.

Afrezza is a rapid-acting mealtime insulin therapy in late-stage clinical investigation for the treatment of adult patients with type-1 and type-2 diabetes mellitus for the control of hyperglycemia. It is a drug–device combination product, consisting of Afrezza inhalation powder (pre-metered into single-use cartridges) and the Afrezza inhaler.

Source: Mannkind Corp.; October 30, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs